Bodi Envi review

Building a separate micro-dose landing page for each molecule, with its own ladder, and then charging the identical monthly figure is the clearest illustration here of why a named low-dose product tells you nothing about its price. The flat-pricing claim is at least the provider's own wording rather than our inference, and it names its fulfillment pharmacy with a street address, which most here does not. Against that: a countdown timer runs on intro rates that are not the standing rates, and the struck-through regular price is set above the provider's own actual rate.

Vs median

Exactly the $169 median

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Same price at every dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Flat at every dose

Price last updated

August 2026

Bodi Envi does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

Bodi Envi is a Shopify-hosted direct-to-consumer telehealth brand selling compounded semaglutide and tirzepatide, a separate micro-dosing line for each, an NAD+ longevity product and an anti-nausea prescription. Intake runs on a separate subdomain with a patient portal on another, and the site advertises same-day clinician visits with treatment plans delivered by secure chat in most states. It names its fulfillment pharmacy outright, with a street address, and states it is licensed in all 50 states. Subscriptions can be paused or canceled at any time with no cancellation fee.

The micro-dose costs exactly what the full dose costs — $169 semaglutide and $249 tirzepatide on both pages — so a microdoser buys a fraction of the drug for the full-dose price, and the dedicated micro-dose page never says so

• The homepage runs a thirty-minute countdown timer against intro rates that are not the standing rates on either molecule
• The homepage's struck-through "regular" semaglutide price is $10 ABOVE the actual product-page rate, so the anchor price is inflated against its own standing figure
• No milligram dose is published anywhere, so "all doses" has no stated upper bound and "micro-dose" has no stated definition
• The storefront's product API returns nothing — everything sells through off-platform pages and an external intake, so no checkout-level price can be confirmed without submitting an intake
• The named pharmacy is a shared fulfillment backend used by several unrelated telehealth brands, so the disclosure is less differentiating than it looks
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

Bodi Envi is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• Microdosing semaglutide
• Microdosing tirzepatide
• What a flat price costs at a low dose
• The true annual cost of a plan